United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer;… Read more
Market Cap & Net Worth: United Therapeutics Corporation (UTHR)
United Therapeutics Corporation (NASDAQ:UTHR) has a market capitalization of $23.25 Billion ($23.25 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #917 globally and #713 in its home market, demonstrating a 2.05% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying United Therapeutics Corporation's stock price $540.02 by its total outstanding shares 43056599 (43.06 Million).
United Therapeutics Corporation Market Cap History: 2015 to 2026
United Therapeutics Corporation's market capitalization history from 2015 to 2026. Data shows growth from $6.74 Billion to $23.25 Billion (14.92% CAGR).
Index Memberships
United Therapeutics Corporation is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$879.22 Billion | 2.44% | #9 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 1.86% | #8 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.96% | #15 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.06% | #125 of 3165 |
|
S&P Midcap 400
MID
|
$3.04 Trillion | 0.50% | #11 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 1.39% | #9 of 263 |
Weight: United Therapeutics Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
United Therapeutics Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how United Therapeutics Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.28x
United Therapeutics Corporation's market cap is 5.28 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
12.71x
United Therapeutics Corporation's market cap is 12.71 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $6.74 Billion | $1.47 Billion | $651.64 Million | 4.60x | 10.35x |
| 2016 | $6.18 Billion | $1.60 Billion | $713.70 Million | 3.86x | 8.65x |
| 2017 | $6.37 Billion | $1.73 Billion | $417.90 Million | 3.69x | 15.24x |
| 2018 | $4.69 Billion | $1.63 Billion | $589.20 Million | 2.88x | 7.96x |
| 2019 | $3.79 Billion | $1.45 Billion | -$104.50 Million | 2.62x | N/A |
| 2020 | $6.54 Billion | $1.48 Billion | $514.80 Million | 4.41x | 12.70x |
| 2021 | $9.30 Billion | $1.69 Billion | $475.80 Million | 5.52x | 19.55x |
| 2022 | $11.97 Billion | $1.94 Billion | $727.30 Million | 6.18x | 16.46x |
| 2023 | $9.47 Billion | $2.33 Billion | $984.80 Million | 4.07x | 9.61x |
| 2024 | $15.19 Billion | $2.88 Billion | $1.20 Billion | 5.28x | 12.71x |
Competitor Companies of UTHR by Market Capitalization
Companies near United Therapeutics Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to United Therapeutics Corporation by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Sandoz Group AG (OTCQX:SDZXF): Ranked #1127 globally with a market cap of $17.13 Billion USD.
- MERCK Kommanditgesellschaft auf Aktien (PINK:MKGAF): Ranked #1166 globally with a market cap of $16.25 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #1127 | Sandoz Group AG | OTCQX:SDZXF | $17.13 Billion | $41.36 |
| #1166 | MERCK Kommanditgesellschaft auf Aktien | PINK:MKGAF | $16.25 Billion | $125.45 |
United Therapeutics Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, United Therapeutics Corporation's market cap moved from $6.74 Billion to $ 23.25 Billion, with a yearly change of 14.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $23.25 Billion | +10.83% |
| 2025 | $20.98 Billion | +38.09% |
| 2024 | $15.19 Billion | +60.46% |
| 2023 | $9.47 Billion | -20.93% |
| 2022 | $11.97 Billion | +28.70% |
| 2021 | $9.30 Billion | +42.35% |
| 2020 | $6.54 Billion | +72.33% |
| 2019 | $3.79 Billion | -19.12% |
| 2018 | $4.69 Billion | -26.39% |
| 2017 | $6.37 Billion | +3.15% |
| 2016 | $6.18 Billion | -8.42% |
| 2015 | $6.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of United Therapeutics Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.25 Billion USD |
| MoneyControl | $23.25 Billion USD |
| MarketWatch | $23.25 Billion USD |
| marketcap.company | $23.25 Billion USD |
| Reuters | $23.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.